Literature DB >> 8880898

Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein.

S J Lydford1, K C McKechnie, P Leff.   

Abstract

In isolated rings of rabbit saphenous vein (RbSV) pre-contracted with 40 mM KCl, Prostaglandin E2 (PGE2), BW245C (a DP-receptor agonist) and PGD2 caused concentration-dependent relaxations with mean potencies (EC50) of 0.5, 38 and 114 nM respectively. The DP-receptor antagonist, BW A868C, antagonized BW245C concentration-effect (E/[A]) curves, although the corresponding Schild plot had a slope less than unity and displayed a clear infection. Analysis of the data yielded two pKB estimates of 8.5 and 4.9, the higher estimate being consistent with antagonism at DP-receptors. The pA2 estimate of 5.1 obtained for BW A868C against PGE2 was not statistically different to the lower pKB of 4.9 obtained against BW245C, and is probably indicative of antagonism at the EP4-receptor. PGD2 mediated responses were also antagonized by BW A868C, however the resultant E/[A] curves were 'bell shaped' in nature. The weak EP4-receptor antagonist AH23848B, also antagonized BW245C and PGD2 responses, yielding pA2 estimates of 5.6 and 5.5 respectively. These results suggest that in the RbSV, BW245C and PGD2 are nonselective agonists mediating relaxations through DP- and EP4-receptors. BW A868C also displayed an affinity for DP-receptors in this preparation, in addition to a second receptor subtype, presumably the EP4-receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880898     DOI: 10.1016/0090-6980(96)00058-5

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  5 in total

1.  Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.

Authors:  Richard J Wilson; Heather Giles
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation.

Authors:  C Rouaud; M Delaforge; M Anger-Leroy; G Le Filliatre; M Finet; R Hanf
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Prostanoid receptors involved in the relaxation of human pulmonary vessels.

Authors:  L Walch; C Labat; J P Gascard; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.

Authors:  Richard J Wilson; Gerard M P Giblin; Susan Roomans; Sharron A Rhodes; Kerri-Ann Cartwright; Vanessa J Shield; Jason Brown; Alan Wise; Jannatara Chowdhury; Sara Pritchard; Jim Coote; Lloyd S Noel; Terry Kenakin; Cynthia L Burns-Kurtis; Valerie Morrison; David W Gray; Heather Giles
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.